Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N-(phenylacetyl) doxorubicin in combination with folate-conjugated PGA

Journal of Pharmaceutical Sciences

Volumn 95, Issue 10, 2006, Pages 2266-2275

  Zhang, Qi ^a   Xiang, Guangya ^a   Zhang, Youjiu ^b   Yang, Keya ^b   Fan, Wo ^b   Lin, Jialiang ^a   Zeng, Fanbo ^a   Wu, Jizhou ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Chemotherapy; Doxorubicin; Folate receptor; Folate directed enzyme prodrug therapy (FDEPT); Penicillin G amidase

Indexed keywords

DOXORUBICIN; DOXORUBICIN DERIVATIVE; FOLATE RECEPTOR; FOLIC ACID; IODINE 125; N (PHENYLACETYL)DOXORUBICIN; PENICILLIN DERIVATIVE; PENICILLIN G AMIDASE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SENSITIVITY; DRUG SYNTHESIS; FEMALE; FLUORESCENCE; HELA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MOUSE; NONHUMAN; TUMOR CELL;

EID: 33750032952     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20714     Document Type: Article

References (30)

1. Hilgenbrink AE, Low PS. 2005. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci 94:2135-2146.
2. Turk MJ, Waters DJ, Low PS. 2004. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 213:165-172.
3. Figini M, Ferri R, Mezzanzanica D, et al. 2003. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther 10:1018-1025.
4. Wu M, Gunning W, Ratnam M. 1999. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 8:775-782.
5. Lu Y, Low PS. 2002. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675-693.
6. Toffoli G, Corona G, Tolusso B, Sartor F, Sorio R, Mini E, Boiocchi M. 2000. Resistance to methotrexate in SKOV-3 cell lines after chronic exposure to carbamazepine is associated with a decreased expression of folate receptor. Int J Cancer 85:683-690.
7. Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. 2004. Ligand binding and kinetics of folate receptor recycling in vivo: Impact on receptor-mediated drug delivery. Mol Pharmacol 66:1406-1414.
8. Sabharanjak S, Mayor S. 2004. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 56:1099-1109.
9. Birn H, Zhai X, Holm J, et al. 2005. Megalin binds and mediates cellular internalization of folate binding protein. FEBS J 272:4423-4430.
10. Low PS. 2004. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 56:1055-1058.
11. Bagshawe KD, Sharma SK, Begent RH. 2004. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 4:1777-1789.
12. Rooseboom M. 2004. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53-102.
13. Wu W, Luo Y, Sun C, et al. 2006. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res 66:970-980.
14. Deonarain MP, Epenetos AA. 1994. Targeting enzymes for cancer therapy: Old enzymes in new roles. Br J Cancer 70:786-794.
15. Harding FA, Liu AD, Stickler M, et al. 2005. A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy. Mol Cancer Ther 4:1791-1800.
16. Iznaga-Escobar N, Mishra AK, Perez-Rodriguez R. 2004. Factors affecting pharmacokinetics of monoclonal antibodies: A review article. Methods Find Exp Clin Pharmacol 26:123-127.
17. Schaedel O, Reiter Y. 2006. Antibodies and their fragments as anti-cancer agents. Curr Pharm Des 12:363-378.
18. Sharma SK. 1996. Immune response in ADEPT. Adv Drug Deliv Rev 22:269-288.
19. Mayer A, Sharma SK, Tolner B, et al. 2004. Modifying an immunogenic epitope on a therapeutic protein: A step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br J Cancer 90:2402-2410.
20. Vrudhula VM, Senter PD, Fisher KJ, Wallace PM. 1993. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidabc conjugate. J Med Chem 36:919-928.
21. Leamon CP, Low PS. 1991. Delivery of macromolecules into living cells: A method that exploits folate receptor endocytosis. Proc Natl Acad Sci 88:5572-5576.
22. Lu Y, Lowe DA, Kennedy MD, Low PS. 1999. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. J Drug Targeting 7:43-53.
23. Lowe DA, Romancik G, Elander RP. 1986. Enzymatic hydrolysis of penicillin V to 6-aminopenicillanic acid by fusarium oxysporum. Biotechnol Lett 8:151-156.
24. Sobal G, Resch U, Sinzinger H. 2004. Modification of low-density lipoprotein by different radioiodination methods. Nucl Med Biol 31:381-388.
25. Shinoda T, Takagi A, Maeda A, et al. 1998. In vivo fate of folate-BSA in non-tumor- and tumor-bearing mice. J Pharm Sci 87:1521-1526.
26. Leamon CP, Reddy JA. 2004. Folate-targeted chemotherapy. Adv Drug Deliv Rev 56:1127-1141.
27. Leamon CP, DePrince RB, Hendren RW. 1999. Folate-mediated drug delivery: Effect of alternative conjugation chemistry. J Drug Targeting 7:157-169.
28. Leamon CP, Pastan I, Low PS. 1993. Cytotoxicity of folate-pseudomonas exotoxin conjugate toward tumor cells. J Bio Chem 268:24847-24854.
29. Miotti S, Bagnoli M, Ottone F, et al. 1997. Simultaneous activity of two different mechanisms of folate transport in ovarian carcinoma cell lines. J Cell Bio 65:479-491.
30. Atkinson SF, Bettinger T, Seymour LW, et al. 2001. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J Bio Chem 276:27930-27935.